Accelerating the development of mRNA vaccines and therapeutics requires the selection and use of raw materials designed to meet critical process, scale, quality and regulatory needs. Choosing appropriate materials saves scientists both time and money.

Join David Vaillencourt, CEO, The GMP Collective and Darwin Millard, The Spock of Cannabis in this free webinar which will provide an update on cannabis standardization from ASTM and what the future has in store.